Kim Magaly Pabst

8PUBLICATIONS
31CO-AUTHORS
Haematological tumoursMedical biotechnology diagnostics (incl. biosensors)Radiation therapyPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 07, 2026
Distribution and prognostic significance of myelotoxicity in newly diagnosed glioblastoma in a real-life cohort: Time to treat more aggressively?

Christoph Oster, Pia Reineck, Teresa Schmidt

|Nov 25, 2025
Potential value of [68Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis.

Kim M Pabst, Sophie C Siegmund, Adrien Holzgreve

|Mar 12, 2025
FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?

Irene García Megías, Ludmila Santiago Almeida, Adriana K Calapaquí Terán

|Aug 29, 2024
Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study.

Kim M Pabst, Riccardo Mei, Katharina Lückerath

|Jul 18, 2024
[68Ga]Ga-FAPI versus 2-[18F]FDG PET/CT in patients with autoimmune thyroiditis: a case control study.

Kim M Pabst, Lukas Kessler, Justin Ferdinandus

|Sep 09, 2023
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.

Matthias Jeschke, Johannes M Ludwig, Catherine Leyh

Pageof 2

Frequent Collaborators

2 joint publications

Ken Herrmann

1 joint publications

Wolfgang P Fendler

1 joint publications

Lukas Kessler

1 joint publications

Pedro Fragoso Costa